Mounjaro and Prediabetes: Can Tirzepatide Prevent Type 2 Diabetes?

Mounjaro prediabetes is one of the most searched topics among patients considering tirzepatide for weight loss, and for good reason. If your blood sugar sits in the prediabetes range, you face a real risk of progressing to type 2 diabetes within five to ten years. The question is whether treatment with tirzepatide can change that trajectory.

The short answer is yes. Three-year clinical trial data now shows that tirzepatide reduces the risk of progressing from prediabetes to type 2 diabetes by 94 per cent. That figure is not a projection or a model; it comes directly from the SURMOUNT-1 extension study published in the New England Journal of Medicine. Below, we explain what the evidence actually shows, who stands to benefit most, and what monitoring looks like in practice.

In the SURMOUNT-1 three-year extension study, participants with prediabetes who took tirzepatide at the maximum tolerated dose saw a 94 per cent reduction in progression to type 2 diabetes compared to placebo. Additionally, 95 per cent of participants who had prediabetes at baseline reverted to normal glucose tolerance. This is the strongest diabetes-prevention result from any single pharmacological intervention studied to date.

Prediabetes means your fasting blood glucose or HbA1c levels are higher than normal but not yet high enough to meet the diagnostic threshold for type 2 diabetes. In UK clinical practice, this typically means an HbA1c of 42 to 47 mmol/mol, or a fasting plasma glucose of 5.5 to 6.9 mmol/L.

NICE guideline NG28 estimates that without intervention, roughly 5 to 10 per cent of people with prediabetes progress to type 2 diabetes each year. Over a decade, that cumulative risk is substantial. The condition is not benign even before full diabetes develops: prediabetes is independently associated with increased cardiovascular risk, fatty liver disease, and chronic kidney disease.

The challenge is that prediabetes rarely produces symptoms. Many patients only discover it through routine blood tests or when they begin a weight management consultation. This is one reason why baseline blood work is a standard part of the assessment at CutKilo before prescribing Mounjaro.

The SURMOUNT-1 trial originally enrolled adults with obesity or overweight (BMI 27 or above with at least one weight-related comorbidity) without type 2 diabetes. The three-year extension, published in the NEJM in 2024, followed participants who continued on tirzepatide for a total of 176 weeks.

Among those who had prediabetes at baseline, the key findings were striking. Participants on tirzepatide experienced a 94 per cent relative risk reduction in progression to type 2 diabetes compared to placebo. Meanwhile, 95 per cent of those with prediabetes at enrolment reverted to normoglycaemia, meaning their blood sugar returned to a completely normal range.

These results are notably stronger than the landmark Diabetes Prevention Programme trial, which showed a 58 per cent reduction with intensive lifestyle intervention alone. The SURMOUNT-1 data suggest that the combination of significant weight loss and tirzepatide’s direct metabolic effects produces a benefit that exceeds what lifestyle changes or older medications have achieved independently.

The prevention of type 2 diabetes is not simply about weight loss. Tirzepatide is a dual GIP and GLP-1 receptor agonist, and this dual mechanism has direct effects on the pancreatic beta cells that produce insulin.

A post-hoc analysis published in Diabetes Care in 2025 examined beta-cell function markers in SURMOUNT participants. The data showed improvements in both first-phase and second-phase insulin secretion, along with enhanced insulin sensitivity. In practical terms, tirzepatide appears to help the pancreas work more efficiently, restoring a pattern of insulin release that is closer to normal.

This matters because beta-cell decline is the central pathological process in the development of type 2 diabetes. By the time someone is diagnosed with T2D, they have typically lost around 50 per cent of their beta-cell function. Intervening at the prediabetes stage, when beta-cell reserve is still substantial, offers the best window for meaningful reversal. If you already have type 2 diabetes and want to understand how tirzepatide helps manage blood sugar, our guide to Mounjaro and type 2 diabetes covers the clinical evidence in detail.

Tirzepatide is currently licensed in the UK for chronic weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity. Prediabetes qualifies as a weight-related comorbidity under prescribing guidelines.

Patients who may benefit most from treatment include those with a BMI of 27 or above and confirmed prediabetes on blood testing, a strong family history of type 2 diabetes, a history of gestational diabetes, polycystic ovary syndrome with insulin resistance, or central adiposity with a waist circumference above recommended thresholds (94 cm for men, 80 cm for women in the UK).

At CutKilo, our doctors review your HbA1c, fasting glucose, and metabolic risk profile as part of the initial consultation. If prediabetes is identified, it informs both the treatment rationale and the monitoring schedule throughout your programme.

Tracking metabolic improvement during treatment requires more than stepping on the scales. While weight loss is an important outcome, the metabolic changes that protect against diabetes, including improvements in insulin sensitivity, visceral fat reduction, and beta-cell recovery, are not visible on a bathroom scale.

Blood tests at three-month intervals (HbA1c and fasting glucose at minimum) allow your doctor to track glycaemic improvement objectively. For patients who want a more detailed picture of body composition changes, DEXA London, CutKilo’s sister service at the same 86 Harley Street clinic, offers body composition scanning that quantifies visceral fat, lean mass, and regional fat distribution, all of which are relevant to metabolic risk.

A 2025 analysis published in Diabetes, Obesity and Metabolism examined 10-year cardiovascular disease risk scores in SURMOUNT participants and found significant reductions in estimated CVD risk alongside the glycaemic improvements. This underscores why metabolic monitoring should look beyond glucose alone.

Tirzepatide is not a standalone solution. The strongest outcomes in clinical trials occurred in participants who combined pharmacotherapy with lifestyle modifications. For patients with prediabetes, several evidence-based strategies complement treatment.

Resistance training at least twice weekly helps preserve lean muscle mass and improves insulin sensitivity independently of weight loss. A diet emphasising whole foods, adequate protein (1.2 to 1.6 g per kg of body weight daily), and fibre supports both glycaemic control and satiety. Limiting refined carbohydrates and ultra-processed foods reduces postprandial glucose spikes. Regular sleep of seven to nine hours per night supports insulin sensitivity, and stress management matters because chronically elevated cortisol impairs glucose regulation.

These are not optional extras. NICE NG28 recommends intensive lifestyle intervention as the foundation of prediabetes management, and tirzepatide works best when layered on top of these habits rather than used as a substitute.

The SURMOUNT-1 three-year extension data represents the most compelling evidence to date that pharmacological intervention can prevent type 2 diabetes in people with prediabetes and obesity. A 94 per cent reduction in progression to T2D, combined with 95 per cent reversion to normal glucose tolerance, sets a new benchmark. Tirzepatide achieves this through the dual mechanism of sustained weight loss and direct improvement in beta-cell function and insulin sensitivity.

For patients with prediabetes who qualify for treatment, the window of opportunity is now. Intervening before beta-cell function declines further offers the best chance of avoiding type 2 diabetes altogether, rather than managing it after it arrives.

Q: Is Mounjaro approved specifically for prediabetes in the UK?

Tirzepatide (Mounjaro) is licensed in the UK for chronic weight management in adults with a BMI of 30 or above, or 27 or above with a weight-related comorbidity. Prediabetes counts as a qualifying comorbidity, so eligible patients with prediabetes can be prescribed tirzepatide for weight management, with the metabolic benefits as an additional clinical outcome.

Q: How quickly can Mounjaro reverse prediabetes?

In the SURMOUNT-1 trial, significant glycaemic improvements were observed within the first 24 weeks of treatment. However, the strongest prevention data comes from the three-year extension, suggesting that sustained treatment produces the most durable metabolic benefits. Your doctor will monitor your HbA1c at regular intervals to track your individual response.

Q: Will my blood sugar stay normal if I stop taking Mounjaro?

The SURMOUNT-1 data showed that some weight regain and metabolic changes occurred after treatment discontinuation. Maintaining lifestyle modifications, including a healthy diet, regular exercise, and weight management, is essential for preserving the metabolic improvements achieved during treatment. Your doctor will discuss a long-term plan tailored to your situation.

Q: Can I take Mounjaro if I already have type 2 diabetes?

Yes. Tirzepatide is also approved for the treatment of type 2 diabetes (marketed as Mounjaro for weight management and as a diabetes treatment). If you have established T2D, the prescribing pathway and monitoring schedule differ from the prediabetes scenario. Speak to your doctor about which approach is appropriate for you.

Q: Do I need blood tests before starting Mounjaro at CutKilo?

Yes. All patients complete a medical questionnaire and have baseline blood work reviewed before prescribing. This includes HbA1c and fasting glucose, which identify prediabetes or diabetes. If these results are not recent, your CutKilo doctor will arrange testing before initiating treatment.

Mounjaro prediabetes is one of the most searched topics among patients considering tirzepatide for weight loss, and for good reason. If your blood sugar sits in the prediabetes range, you face a real risk of progressing to type 2 diabetes within five to ten years. The question is whether treatment with tirzepatide can change that trajectory.

The short answer is yes. Three-year clinical trial data now shows that tirzepatide reduces the risk of progressing from prediabetes to type 2 diabetes by 94 per cent. That figure is not a projection or a model; it comes directly from the SURMOUNT-1 extension study published in the New England Journal of Medicine. Below, we explain what the evidence actually shows, who stands to benefit most, and what monitoring looks like in practice.

In the SURMOUNT-1 three-year extension study, participants with prediabetes who took tirzepatide at the maximum tolerated dose saw a 94 per cent reduction in progression to type 2 diabetes compared to placebo. Additionally, 95 per cent of participants who had prediabetes at baseline reverted to normal glucose tolerance. This is the strongest diabetes-prevention result from any single pharmacological intervention studied to date.

Prediabetes means your fasting blood glucose or HbA1c levels are higher than normal but not yet high enough to meet the diagnostic threshold for type 2 diabetes. In UK clinical practice, this typically means an HbA1c of 42 to 47 mmol/mol, or a fasting plasma glucose of 5.5 to 6.9 mmol/L.

NICE guideline NG28 estimates that without intervention, roughly 5 to 10 per cent of people with prediabetes progress to type 2 diabetes each year. Over a decade, that cumulative risk is substantial. The condition is not benign even before full diabetes develops: prediabetes is independently associated with increased cardiovascular risk, fatty liver disease, and chronic kidney disease.

The challenge is that prediabetes rarely produces symptoms. Many patients only discover it through routine blood tests or when they begin a weight management consultation. This is one reason why baseline blood work is a standard part of the assessment at CutKilo before prescribing Mounjaro.

The SURMOUNT-1 trial originally enrolled adults with obesity or overweight (BMI 27 or above with at least one weight-related comorbidity) without type 2 diabetes. The three-year extension, published in the NEJM in 2024, followed participants who continued on tirzepatide for a total of 176 weeks.

Among those who had prediabetes at baseline, the key findings were striking. Participants on tirzepatide experienced a 94 per cent relative risk reduction in progression to type 2 diabetes compared to placebo. Meanwhile, 95 per cent of those with prediabetes at enrolment reverted to normoglycaemia, meaning their blood sugar returned to a completely normal range.

These results are notably stronger than the landmark Diabetes Prevention Programme trial, which showed a 58 per cent reduction with intensive lifestyle intervention alone. The SURMOUNT-1 data suggest that the combination of significant weight loss and tirzepatide’s direct metabolic effects produces a benefit that exceeds what lifestyle changes or older medications have achieved independently.

The prevention of type 2 diabetes is not simply about weight loss. Tirzepatide is a dual GIP and GLP-1 receptor agonist, and this dual mechanism has direct effects on the pancreatic beta cells that produce insulin.

A post-hoc analysis published in Diabetes Care in 2025 examined beta-cell function markers in SURMOUNT participants. The data showed improvements in both first-phase and second-phase insulin secretion, along with enhanced insulin sensitivity. In practical terms, tirzepatide appears to help the pancreas work more efficiently, restoring a pattern of insulin release that is closer to normal.

This matters because beta-cell decline is the central pathological process in the development of type 2 diabetes. By the time someone is diagnosed with T2D, they have typically lost around 50 per cent of their beta-cell function. Intervening at the prediabetes stage, when beta-cell reserve is still substantial, offers the best window for meaningful reversal. If you already have type 2 diabetes and want to understand how tirzepatide helps manage blood sugar, our guide to Mounjaro and type 2 diabetes covers the clinical evidence in detail.

Tirzepatide is currently licensed in the UK for chronic weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity. Prediabetes qualifies as a weight-related comorbidity under prescribing guidelines.

Patients who may benefit most from treatment include those with a BMI of 27 or above and confirmed prediabetes on blood testing, a strong family history of type 2 diabetes, a history of gestational diabetes, polycystic ovary syndrome with insulin resistance, or central adiposity with a waist circumference above recommended thresholds (94 cm for men, 80 cm for women in the UK).

At CutKilo, our doctors review your HbA1c, fasting glucose, and metabolic risk profile as part of the initial consultation. If prediabetes is identified, it informs both the treatment rationale and the monitoring schedule throughout your programme.

Tracking metabolic improvement during treatment requires more than stepping on the scales. While weight loss is an important outcome, the metabolic changes that protect against diabetes, including improvements in insulin sensitivity, visceral fat reduction, and beta-cell recovery, are not visible on a bathroom scale.

Blood tests at three-month intervals (HbA1c and fasting glucose at minimum) allow your doctor to track glycaemic improvement objectively. For patients who want a more detailed picture of body composition changes, DEXA London, CutKilo’s sister service at the same 86 Harley Street clinic, offers body composition scanning that quantifies visceral fat, lean mass, and regional fat distribution, all of which are relevant to metabolic risk.

A 2025 analysis published in Diabetes, Obesity and Metabolism examined 10-year cardiovascular disease risk scores in SURMOUNT participants and found significant reductions in estimated CVD risk alongside the glycaemic improvements. This underscores why metabolic monitoring should look beyond glucose alone.

Tirzepatide is not a standalone solution. The strongest outcomes in clinical trials occurred in participants who combined pharmacotherapy with lifestyle modifications. For patients with prediabetes, several evidence-based strategies complement treatment.

Resistance training at least twice weekly helps preserve lean muscle mass and improves insulin sensitivity independently of weight loss. A diet emphasising whole foods, adequate protein (1.2 to 1.6 g per kg of body weight daily), and fibre supports both glycaemic control and satiety. Limiting refined carbohydrates and ultra-processed foods reduces postprandial glucose spikes. Regular sleep of seven to nine hours per night supports insulin sensitivity, and stress management matters because chronically elevated cortisol impairs glucose regulation.

These are not optional extras. NICE NG28 recommends intensive lifestyle intervention as the foundation of prediabetes management, and tirzepatide works best when layered on top of these habits rather than used as a substitute.

The SURMOUNT-1 three-year extension data represents the most compelling evidence to date that pharmacological intervention can prevent type 2 diabetes in people with prediabetes and obesity. A 94 per cent reduction in progression to T2D, combined with 95 per cent reversion to normal glucose tolerance, sets a new benchmark. Tirzepatide achieves this through the dual mechanism of sustained weight loss and direct improvement in beta-cell function and insulin sensitivity.

For patients with prediabetes who qualify for treatment, the window of opportunity is now. Intervening before beta-cell function declines further offers the best chance of avoiding type 2 diabetes altogether, rather than managing it after it arrives.

Q: Is Mounjaro approved specifically for prediabetes in the UK?

Tirzepatide (Mounjaro) is licensed in the UK for chronic weight management in adults with a BMI of 30 or above, or 27 or above with a weight-related comorbidity. Prediabetes counts as a qualifying comorbidity, so eligible patients with prediabetes can be prescribed tirzepatide for weight management, with the metabolic benefits as an additional clinical outcome.

Q: How quickly can Mounjaro reverse prediabetes?

In the SURMOUNT-1 trial, significant glycaemic improvements were observed within the first 24 weeks of treatment. However, the strongest prevention data comes from the three-year extension, suggesting that sustained treatment produces the most durable metabolic benefits. Your doctor will monitor your HbA1c at regular intervals to track your individual response.

Q: Will my blood sugar stay normal if I stop taking Mounjaro?

The SURMOUNT-1 data showed that some weight regain and metabolic changes occurred after treatment discontinuation. Maintaining lifestyle modifications, including a healthy diet, regular exercise, and weight management, is essential for preserving the metabolic improvements achieved during treatment. Your doctor will discuss a long-term plan tailored to your situation.

Q: Can I take Mounjaro if I already have type 2 diabetes?

Yes. Tirzepatide is also approved for the treatment of type 2 diabetes (marketed as Mounjaro for weight management and as a diabetes treatment). If you have established T2D, the prescribing pathway and monitoring schedule differ from the prediabetes scenario. Speak to your doctor about which approach is appropriate for you.

Q: Do I need blood tests before starting Mounjaro at CutKilo?

Yes. All patients complete a medical questionnaire and have baseline blood work reviewed before prescribing. This includes HbA1c and fasting glucose, which identify prediabetes or diabetes. If these results are not recent, your CutKilo doctor will arrange testing before initiating treatment.

Mounjaro prediabetes is one of the most searched topics among patients considering tirzepatide for weight loss, and for good reason. If your blood sugar sits in the prediabetes range, you face a real risk of progressing to type 2 diabetes within five to ten years. The question is whether treatment with tirzepatide can change that trajectory.

The short answer is yes. Three-year clinical trial data now shows that tirzepatide reduces the risk of progressing from prediabetes to type 2 diabetes by 94 per cent. That figure is not a projection or a model; it comes directly from the SURMOUNT-1 extension study published in the New England Journal of Medicine. Below, we explain what the evidence actually shows, who stands to benefit most, and what monitoring looks like in practice.

In the SURMOUNT-1 three-year extension study, participants with prediabetes who took tirzepatide at the maximum tolerated dose saw a 94 per cent reduction in progression to type 2 diabetes compared to placebo. Additionally, 95 per cent of participants who had prediabetes at baseline reverted to normal glucose tolerance. This is the strongest diabetes-prevention result from any single pharmacological intervention studied to date.

Prediabetes means your fasting blood glucose or HbA1c levels are higher than normal but not yet high enough to meet the diagnostic threshold for type 2 diabetes. In UK clinical practice, this typically means an HbA1c of 42 to 47 mmol/mol, or a fasting plasma glucose of 5.5 to 6.9 mmol/L.

NICE guideline NG28 estimates that without intervention, roughly 5 to 10 per cent of people with prediabetes progress to type 2 diabetes each year. Over a decade, that cumulative risk is substantial. The condition is not benign even before full diabetes develops: prediabetes is independently associated with increased cardiovascular risk, fatty liver disease, and chronic kidney disease.

The challenge is that prediabetes rarely produces symptoms. Many patients only discover it through routine blood tests or when they begin a weight management consultation. This is one reason why baseline blood work is a standard part of the assessment at CutKilo before prescribing Mounjaro.

The SURMOUNT-1 trial originally enrolled adults with obesity or overweight (BMI 27 or above with at least one weight-related comorbidity) without type 2 diabetes. The three-year extension, published in the NEJM in 2024, followed participants who continued on tirzepatide for a total of 176 weeks.

Among those who had prediabetes at baseline, the key findings were striking. Participants on tirzepatide experienced a 94 per cent relative risk reduction in progression to type 2 diabetes compared to placebo. Meanwhile, 95 per cent of those with prediabetes at enrolment reverted to normoglycaemia, meaning their blood sugar returned to a completely normal range.

These results are notably stronger than the landmark Diabetes Prevention Programme trial, which showed a 58 per cent reduction with intensive lifestyle intervention alone. The SURMOUNT-1 data suggest that the combination of significant weight loss and tirzepatide’s direct metabolic effects produces a benefit that exceeds what lifestyle changes or older medications have achieved independently.

The prevention of type 2 diabetes is not simply about weight loss. Tirzepatide is a dual GIP and GLP-1 receptor agonist, and this dual mechanism has direct effects on the pancreatic beta cells that produce insulin.

A post-hoc analysis published in Diabetes Care in 2025 examined beta-cell function markers in SURMOUNT participants. The data showed improvements in both first-phase and second-phase insulin secretion, along with enhanced insulin sensitivity. In practical terms, tirzepatide appears to help the pancreas work more efficiently, restoring a pattern of insulin release that is closer to normal.

This matters because beta-cell decline is the central pathological process in the development of type 2 diabetes. By the time someone is diagnosed with T2D, they have typically lost around 50 per cent of their beta-cell function. Intervening at the prediabetes stage, when beta-cell reserve is still substantial, offers the best window for meaningful reversal. If you already have type 2 diabetes and want to understand how tirzepatide helps manage blood sugar, our guide to Mounjaro and type 2 diabetes covers the clinical evidence in detail.

Tirzepatide is currently licensed in the UK for chronic weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity. Prediabetes qualifies as a weight-related comorbidity under prescribing guidelines.

Patients who may benefit most from treatment include those with a BMI of 27 or above and confirmed prediabetes on blood testing, a strong family history of type 2 diabetes, a history of gestational diabetes, polycystic ovary syndrome with insulin resistance, or central adiposity with a waist circumference above recommended thresholds (94 cm for men, 80 cm for women in the UK).

At CutKilo, our doctors review your HbA1c, fasting glucose, and metabolic risk profile as part of the initial consultation. If prediabetes is identified, it informs both the treatment rationale and the monitoring schedule throughout your programme.

Tracking metabolic improvement during treatment requires more than stepping on the scales. While weight loss is an important outcome, the metabolic changes that protect against diabetes, including improvements in insulin sensitivity, visceral fat reduction, and beta-cell recovery, are not visible on a bathroom scale.

Blood tests at three-month intervals (HbA1c and fasting glucose at minimum) allow your doctor to track glycaemic improvement objectively. For patients who want a more detailed picture of body composition changes, DEXA London, CutKilo’s sister service at the same 86 Harley Street clinic, offers body composition scanning that quantifies visceral fat, lean mass, and regional fat distribution, all of which are relevant to metabolic risk.

A 2025 analysis published in Diabetes, Obesity and Metabolism examined 10-year cardiovascular disease risk scores in SURMOUNT participants and found significant reductions in estimated CVD risk alongside the glycaemic improvements. This underscores why metabolic monitoring should look beyond glucose alone.

Tirzepatide is not a standalone solution. The strongest outcomes in clinical trials occurred in participants who combined pharmacotherapy with lifestyle modifications. For patients with prediabetes, several evidence-based strategies complement treatment.

Resistance training at least twice weekly helps preserve lean muscle mass and improves insulin sensitivity independently of weight loss. A diet emphasising whole foods, adequate protein (1.2 to 1.6 g per kg of body weight daily), and fibre supports both glycaemic control and satiety. Limiting refined carbohydrates and ultra-processed foods reduces postprandial glucose spikes. Regular sleep of seven to nine hours per night supports insulin sensitivity, and stress management matters because chronically elevated cortisol impairs glucose regulation.

These are not optional extras. NICE NG28 recommends intensive lifestyle intervention as the foundation of prediabetes management, and tirzepatide works best when layered on top of these habits rather than used as a substitute.

The SURMOUNT-1 three-year extension data represents the most compelling evidence to date that pharmacological intervention can prevent type 2 diabetes in people with prediabetes and obesity. A 94 per cent reduction in progression to T2D, combined with 95 per cent reversion to normal glucose tolerance, sets a new benchmark. Tirzepatide achieves this through the dual mechanism of sustained weight loss and direct improvement in beta-cell function and insulin sensitivity.

For patients with prediabetes who qualify for treatment, the window of opportunity is now. Intervening before beta-cell function declines further offers the best chance of avoiding type 2 diabetes altogether, rather than managing it after it arrives.

Q: Is Mounjaro approved specifically for prediabetes in the UK?

Tirzepatide (Mounjaro) is licensed in the UK for chronic weight management in adults with a BMI of 30 or above, or 27 or above with a weight-related comorbidity. Prediabetes counts as a qualifying comorbidity, so eligible patients with prediabetes can be prescribed tirzepatide for weight management, with the metabolic benefits as an additional clinical outcome.

Q: How quickly can Mounjaro reverse prediabetes?

In the SURMOUNT-1 trial, significant glycaemic improvements were observed within the first 24 weeks of treatment. However, the strongest prevention data comes from the three-year extension, suggesting that sustained treatment produces the most durable metabolic benefits. Your doctor will monitor your HbA1c at regular intervals to track your individual response.

Q: Will my blood sugar stay normal if I stop taking Mounjaro?

The SURMOUNT-1 data showed that some weight regain and metabolic changes occurred after treatment discontinuation. Maintaining lifestyle modifications, including a healthy diet, regular exercise, and weight management, is essential for preserving the metabolic improvements achieved during treatment. Your doctor will discuss a long-term plan tailored to your situation.

Q: Can I take Mounjaro if I already have type 2 diabetes?

Yes. Tirzepatide is also approved for the treatment of type 2 diabetes (marketed as Mounjaro for weight management and as a diabetes treatment). If you have established T2D, the prescribing pathway and monitoring schedule differ from the prediabetes scenario. Speak to your doctor about which approach is appropriate for you.

Q: Do I need blood tests before starting Mounjaro at CutKilo?

Yes. All patients complete a medical questionnaire and have baseline blood work reviewed before prescribing. This includes HbA1c and fasting glucose, which identify prediabetes or diabetes. If these results are not recent, your CutKilo doctor will arrange testing before initiating treatment.

Mounjaro prediabetes is one of the most searched topics among patients considering tirzepatide for weight loss, and for good reason. If your blood sugar sits in the prediabetes range, you face a real risk of progressing to type 2 diabetes within five to ten years. The question is whether treatment with tirzepatide can change that trajectory.

The short answer is yes. Three-year clinical trial data now shows that tirzepatide reduces the risk of progressing from prediabetes to type 2 diabetes by 94 per cent. That figure is not a projection or a model; it comes directly from the SURMOUNT-1 extension study published in the New England Journal of Medicine. Below, we explain what the evidence actually shows, who stands to benefit most, and what monitoring looks like in practice.

In the SURMOUNT-1 three-year extension study, participants with prediabetes who took tirzepatide at the maximum tolerated dose saw a 94 per cent reduction in progression to type 2 diabetes compared to placebo. Additionally, 95 per cent of participants who had prediabetes at baseline reverted to normal glucose tolerance. This is the strongest diabetes-prevention result from any single pharmacological intervention studied to date.

Prediabetes means your fasting blood glucose or HbA1c levels are higher than normal but not yet high enough to meet the diagnostic threshold for type 2 diabetes. In UK clinical practice, this typically means an HbA1c of 42 to 47 mmol/mol, or a fasting plasma glucose of 5.5 to 6.9 mmol/L.

NICE guideline NG28 estimates that without intervention, roughly 5 to 10 per cent of people with prediabetes progress to type 2 diabetes each year. Over a decade, that cumulative risk is substantial. The condition is not benign even before full diabetes develops: prediabetes is independently associated with increased cardiovascular risk, fatty liver disease, and chronic kidney disease.

The challenge is that prediabetes rarely produces symptoms. Many patients only discover it through routine blood tests or when they begin a weight management consultation. This is one reason why baseline blood work is a standard part of the assessment at CutKilo before prescribing Mounjaro.

The SURMOUNT-1 trial originally enrolled adults with obesity or overweight (BMI 27 or above with at least one weight-related comorbidity) without type 2 diabetes. The three-year extension, published in the NEJM in 2024, followed participants who continued on tirzepatide for a total of 176 weeks.

Among those who had prediabetes at baseline, the key findings were striking. Participants on tirzepatide experienced a 94 per cent relative risk reduction in progression to type 2 diabetes compared to placebo. Meanwhile, 95 per cent of those with prediabetes at enrolment reverted to normoglycaemia, meaning their blood sugar returned to a completely normal range.

These results are notably stronger than the landmark Diabetes Prevention Programme trial, which showed a 58 per cent reduction with intensive lifestyle intervention alone. The SURMOUNT-1 data suggest that the combination of significant weight loss and tirzepatide’s direct metabolic effects produces a benefit that exceeds what lifestyle changes or older medications have achieved independently.

The prevention of type 2 diabetes is not simply about weight loss. Tirzepatide is a dual GIP and GLP-1 receptor agonist, and this dual mechanism has direct effects on the pancreatic beta cells that produce insulin.

A post-hoc analysis published in Diabetes Care in 2025 examined beta-cell function markers in SURMOUNT participants. The data showed improvements in both first-phase and second-phase insulin secretion, along with enhanced insulin sensitivity. In practical terms, tirzepatide appears to help the pancreas work more efficiently, restoring a pattern of insulin release that is closer to normal.

This matters because beta-cell decline is the central pathological process in the development of type 2 diabetes. By the time someone is diagnosed with T2D, they have typically lost around 50 per cent of their beta-cell function. Intervening at the prediabetes stage, when beta-cell reserve is still substantial, offers the best window for meaningful reversal. If you already have type 2 diabetes and want to understand how tirzepatide helps manage blood sugar, our guide to Mounjaro and type 2 diabetes covers the clinical evidence in detail.

Tirzepatide is currently licensed in the UK for chronic weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity. Prediabetes qualifies as a weight-related comorbidity under prescribing guidelines.

Patients who may benefit most from treatment include those with a BMI of 27 or above and confirmed prediabetes on blood testing, a strong family history of type 2 diabetes, a history of gestational diabetes, polycystic ovary syndrome with insulin resistance, or central adiposity with a waist circumference above recommended thresholds (94 cm for men, 80 cm for women in the UK).

At CutKilo, our doctors review your HbA1c, fasting glucose, and metabolic risk profile as part of the initial consultation. If prediabetes is identified, it informs both the treatment rationale and the monitoring schedule throughout your programme.

Tracking metabolic improvement during treatment requires more than stepping on the scales. While weight loss is an important outcome, the metabolic changes that protect against diabetes, including improvements in insulin sensitivity, visceral fat reduction, and beta-cell recovery, are not visible on a bathroom scale.

Blood tests at three-month intervals (HbA1c and fasting glucose at minimum) allow your doctor to track glycaemic improvement objectively. For patients who want a more detailed picture of body composition changes, DEXA London, CutKilo’s sister service at the same 86 Harley Street clinic, offers body composition scanning that quantifies visceral fat, lean mass, and regional fat distribution, all of which are relevant to metabolic risk.

A 2025 analysis published in Diabetes, Obesity and Metabolism examined 10-year cardiovascular disease risk scores in SURMOUNT participants and found significant reductions in estimated CVD risk alongside the glycaemic improvements. This underscores why metabolic monitoring should look beyond glucose alone.

Tirzepatide is not a standalone solution. The strongest outcomes in clinical trials occurred in participants who combined pharmacotherapy with lifestyle modifications. For patients with prediabetes, several evidence-based strategies complement treatment.

Resistance training at least twice weekly helps preserve lean muscle mass and improves insulin sensitivity independently of weight loss. A diet emphasising whole foods, adequate protein (1.2 to 1.6 g per kg of body weight daily), and fibre supports both glycaemic control and satiety. Limiting refined carbohydrates and ultra-processed foods reduces postprandial glucose spikes. Regular sleep of seven to nine hours per night supports insulin sensitivity, and stress management matters because chronically elevated cortisol impairs glucose regulation.

These are not optional extras. NICE NG28 recommends intensive lifestyle intervention as the foundation of prediabetes management, and tirzepatide works best when layered on top of these habits rather than used as a substitute.

The SURMOUNT-1 three-year extension data represents the most compelling evidence to date that pharmacological intervention can prevent type 2 diabetes in people with prediabetes and obesity. A 94 per cent reduction in progression to T2D, combined with 95 per cent reversion to normal glucose tolerance, sets a new benchmark. Tirzepatide achieves this through the dual mechanism of sustained weight loss and direct improvement in beta-cell function and insulin sensitivity.

For patients with prediabetes who qualify for treatment, the window of opportunity is now. Intervening before beta-cell function declines further offers the best chance of avoiding type 2 diabetes altogether, rather than managing it after it arrives.

Q: Is Mounjaro approved specifically for prediabetes in the UK?

Tirzepatide (Mounjaro) is licensed in the UK for chronic weight management in adults with a BMI of 30 or above, or 27 or above with a weight-related comorbidity. Prediabetes counts as a qualifying comorbidity, so eligible patients with prediabetes can be prescribed tirzepatide for weight management, with the metabolic benefits as an additional clinical outcome.

Q: How quickly can Mounjaro reverse prediabetes?

In the SURMOUNT-1 trial, significant glycaemic improvements were observed within the first 24 weeks of treatment. However, the strongest prevention data comes from the three-year extension, suggesting that sustained treatment produces the most durable metabolic benefits. Your doctor will monitor your HbA1c at regular intervals to track your individual response.

Q: Will my blood sugar stay normal if I stop taking Mounjaro?

The SURMOUNT-1 data showed that some weight regain and metabolic changes occurred after treatment discontinuation. Maintaining lifestyle modifications, including a healthy diet, regular exercise, and weight management, is essential for preserving the metabolic improvements achieved during treatment. Your doctor will discuss a long-term plan tailored to your situation.

Q: Can I take Mounjaro if I already have type 2 diabetes?

Yes. Tirzepatide is also approved for the treatment of type 2 diabetes (marketed as Mounjaro for weight management and as a diabetes treatment). If you have established T2D, the prescribing pathway and monitoring schedule differ from the prediabetes scenario. Speak to your doctor about which approach is appropriate for you.

Q: Do I need blood tests before starting Mounjaro at CutKilo?

Yes. All patients complete a medical questionnaire and have baseline blood work reviewed before prescribing. This includes HbA1c and fasting glucose, which identify prediabetes or diabetes. If these results are not recent, your CutKilo doctor will arrange testing before initiating treatment.